Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2021)

Cogent Biosciences has reported Income from Continuing Operations over the past 5 years, most recently at 25533000.0 for Q4 2021.

  • Quarterly results put Income from Continuing Operations at 25533000.0 for Q4 2021, down 124.27% from a year ago — trailing twelve months through Dec 2021 was 75084000.0 (up 8.5% YoY), and the annual figure for FY2025 was 321736000.0, down 24.78%.
  • Income from Continuing Operations for Q4 2021 was 25533000.0 at Cogent Biosciences, down from 19704000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for COGT hit a ceiling of 2301000.0 in Q4 2019 and a floor of 57176000.0 in Q3 2020.
  • Median Income from Continuing Operations over the past 5 years was 9675500.0 (2018), compared with a mean of 12483400.0.
  • Biggest five-year swings in Income from Continuing Operations: soared 126.77% in 2019 and later crashed 594.78% in 2020.
  • Cogent Biosciences' Income from Continuing Operations stood at 6781000.0 in 2017, then fell by 26.77% to 8596000.0 in 2018, then soared by 126.77% to 2301000.0 in 2019, then crashed by 594.78% to 11385000.0 in 2020, then plummeted by 124.27% to 25533000.0 in 2021.
  • The last three reported values for Income from Continuing Operations were 25533000.0 (Q4 2021), 19704000.0 (Q3 2021), and 17172000.0 (Q2 2021) per Business Quant data.